Loading…
Loading…
Home › All recalls › Prescription medicine
Category
Prescription drugs recalled for contamination, potency or labelling.
Or try another category
1,991 recalls · newest first
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Presence of Particulate Matter.
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Failed Dissolution Specifications
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
Presence of particulate matter: a white thread-like structure in the cartridge
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
Lack of assurance of Sterility: potential product contamination
Lack of assurance of Sterility: potential product contamination
Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
Lack of Assurance of Sterility: Due to FDA inspection observations that it believes may impact product quality.
Chemical contamination; presence of lead and lithium above specification
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.